Although we have investigated that targeting on NLRP3 with MCC950 could significantly alleviate the cardiac phenotype in a ARVC mouse model, more mechanism study should be performed to apply in clinical practice. Here, NLRP3 is linked to arrhythmogenic right ventricular cardiomyopathy.